HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
Top Cited Papers
- 27 March 2008
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 358 (13) , 1409-1411
- https://doi.org/10.1056/nejmc0801440
Abstract
Trastuzumab, an antibody against the protein product of the human epidermal growth factor receptor type 2 (HER2) gene, improves progression-free survival and overall survival when added to chemotherapy in patients with metastatic breast cancer.1 Initial trials enrolled patients with tumors that had a staining intensity of 2+ or 3+ for HER2 on immunohistochemical analysis, but in subsequent studies, the benefit was limited to tumors with HER2 amplification as determined by fluorescence in situ hybridization (FISH). Trastuzumab also improves disease-free survival and overall survival in the adjuvant setting.2Keywords
This publication has 4 references indexed in Scilit:
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Real-World Performance of HER2 Testing--National Surgical Adjuvant Breast and Bowel Project ExperienceJNCI Journal of the National Cancer Institute, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001